FDA rejects Probuphine; Mayday, Mayday, Mayday for Titan shares
This article was originally published in Scrip
May Day was anything but a celebration for Titan Pharmaceuticals, which watched helplessly as its stock lost 80% of its value in morning trading after the FDA rejected the firm's new drug application for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate) – an action the company's executive chairman, Dr Marc Rubin, said came as a surprise.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.